Anti-HIV medications are expensive. Over the course of a year, just one will cost thousands – some over $10,000 – and more than one is needed to treat people with AIDS. These high prices put an unbearable strain on cash-strapped AIDS Drug Assistance Programs, limiting access to lifesaving treatment for those most in need.
Top drug companies are well-compensated for their medical research and development. In 2010, Bristol-Myers Squibb, Johnson & Johnson and Merck each reported over $10 billion in profits. Meanwhile, their markups on HIV meds put patients at risk.
Sign on to our e-letters below to tell pharmaceutical companies to lower prices on HIV medication.
- Gilead: Drug Prices to Die For
- Tell Johnson & Johnson: No More Tears on Drug Pricing
- Urge Bristol-Myers Squibb to lower the price of its AIDS drug Reyataz for state ADAPs
